<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <meta name="author" content="Akshay Gulabrao" />
  <title>Equillium Inc.</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="style.css" />
</head>
<body>
<header id="title-block-header">
<h1 class="title">Equillium Inc.</h1>
<p class="author">Akshay Gulabrao</p>
<p class="date">2025 October 27</p>
</header>
<p><a href="./index.html">Home</a></p>
<p>Equillium Inc.Â currently trades at $1.32 as of 2025/10/23. Their main
drug is EQ504.</p>
<p>The company seems to have found the underlying mechanism that makes
the ABVX drug work. Both companies developed a small molecule that
targets the Aryl Hydrocarbon Receptor (AHR) which modulates the
intestinal epithelial barrier.</p>
<p>The company mentions their drug in posters at popular academic
conferences:</p>
<ul>
<li><a
href="https://www.equilliumbio.com/technology/Presentations-Technology/Presentations-Details/2025/EQ504-A-Novel-AhR-Agonist-That-Promotes-Immune-Tolerance-Through-Modulating-T-Cell-Function/default.aspx">EQ504:
A Novel AhR Agonist That Promotes Immune Tolerance Through Modulating T
Cell Function</a></li>
<li><a
href="https://www.equilliumbio.com/technology/Presentations-Technology/Presentations-Details/2025/EQ504-A-Potent-Derivative-of-the-AhR-Ligand-ITE-Demonstrates-Efficacy-in-Modulating-Inflammation-and-Promoting-Healing-in-DSS-Colitis/default.aspx">EQ504:
A Potent Derivative of the AhR Ligand ITE Demonstrates Efficacy in
Modulating Inflammation and Promoting Healing in DSS-Colitis</a></li>
<li><a
href="https://www.equilliumbio.com/technology/Presentations-Technology/Presentations-Details/2025/Potent-AhR-Agonist-EQ504-Facilitates-Gut-Epithelial-Repair-in-Inflammatory-Disease-Models/default.aspx">Potent
AhR Agonist EQ504 Facilitates Gut Epithelial Repair in Inflammatory
Disease Models</a></li>
</ul>
</body>
</html>
